CD261 (DR4) Monoclonal Antibody (DJR1), PE, eBioscience™, Invitrogen™

Description

Description: The DJR1 monoclonal antibody reacts with human DR4, also known as TRAIL-R1. DR4 binds to TRAIL, activates NF-kappaB, and induces TRAIL-mediated apoptosis. DR4 is expressed by a variety of human tumor cells and at very low level on human leukocytes. Expression has also been found inside the cell on some cell lines (Zhang et al). This has been confirmed with intracellular staining of Jurkat cell line. Please contact tech@ebioscience.com for more information. Applications Reported: The DJR1 antibody has been reported for use in flow cytometric analysis. Applications Tested: This DJR1 antibody has been pre-titrated and tested by flow cytometric analysis of human DR4-transfected cells. This can be used at 5 μL (0.5 μg) per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 μm post-manufacturing filtered.

TRAIL-R1 (CD261, DR4) is a type I transmembrane protein, also called TRAIL receptor 1. The ligand for this DR4 death receptor has been identified and termed TRAIL, which is a member of the TNF family. DR4, as many other receptors (Fas, TNFR1, etc.), mediates apoptosis and NF kappaB activation in many cells and tissues. Apoptosis, a programmed cell death, is a operating process in normal cellular differentiation and development of multicellular organisms. Apoptosis is induced by coupled of certain cytokines (TNF family - TNF, Fas ligand) and their death domain containing receptors (TNFR1, Fas receptor).